COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8 + -T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.
【저자키워드】 SARS-CoV-2, Innate immunity, viral infections, polybacterial mucosal immunotherapy, vaccine immunogenicity, 【초록키워드】 viral infection, Vaccine, COVID-19 vaccine, vaccination, Vaccines, Immunotherapy, SARS-COV-2 infection, SARS-CoV-2 virus, Prophylactic, CD8, Prophylaxis, Protein, mice, K18-hACE2 mice, Bacteria, intranasal, Heterologous, boost, Bacterial, mucosal, Clinical efficacy, administration, innate response, IgA antibodies, viral respiratory infections, cell activation, C57BL/6, responses, heat-inactivated, susceptible, IMPROVE, PROTECT, shown, intranasally, inoculated, the vaccine, intramuscularly, the SARS-CoV-2, 【제목키워드】 COVID-19, immunogenicity, Against,